

Groundbreaking three-year partnership to tackle prostate cancer
Prostate Cancer Foundation of Australia (PCFA) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) have agreed to a landmark three-year
xx Gift of $xx
Or enter your own donation amount
Please complete your details
* Indicates a required field
Telehealth and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations.
Teleheath and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
Excited to have @ANZUPtrials #ENZAp #ProstateCancer #pcsm #ClinicalTrial OS and HRQoL data presented at #GU25 this week by the incomparable @drlouiseemmett - don’t miss it!
📣Excited to announce from Perth, WA, initial participant dosed in the first in-human study #GDISCO; Gemcitabine-Docetaxel Intravesical Synchronous CO-administration for BCG unresponsive HR-NMIBC (ANZUP2403). @ASCO #GU25 @ANZUPtrials @uwanews #SMHS
Great to see @ANZUPtrials #ENZAMET study feature in two Plain Language Summaries this month: & https://bit.ly/40qTC9e @ChrisSweens1 @Prof_IanD @TrialsCentre @cancertrials_ie @CDNCancerTrials @AstellasUS @CancerAustralia
Prostate Cancer Foundation of Australia (PCFA) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) have agreed to a landmark three-year
New research findings of the ENZAMET (ANZUP 1304) study, led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), reveal that
Lutetium-177 PSMA-617 – or LuPSMA – therapy had been shown in previous clinical trials to extend lives, and improve quality-of-life, in patients with advanced metastatic
To assess the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations.
Prostate Cancer Foundation of Australia (PCFA) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) have agreed to a landmark three-year
New research findings of the ENZAMET (ANZUP 1304) study, led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), reveal that
Lutetium-177 PSMA-617 – or LuPSMA – therapy had been shown in previous clinical trials to extend lives, and improve quality-of-life, in patients with advanced metastatic